Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  KOREA EXCHANGE  >  Celltrion, Inc.    A068270   KR7068270008

CELLTRION, INC.

(A068270)
  Report
 SummaryNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Financials (KRW)
Sales 2020 1 496 B
EBIT 2020 569 B
Net income 2020 492 B
Finance 2020 621 B
Yield 2020 0,00%
Sales 2021 1 793 B
EBIT 2021 706 B
Net income 2021 597 B
Finance 2021 1 208 B
Yield 2021 0,01%
P/E ratio 2020 48,5x
P/E ratio 2021 39,8x
EV / Sales2020 15 798x
EV / Sales2021 13 183x
Capitalization 23 642 B
More Financials
Company
Celltrion, Inc. is a Korea-based company mainly engaged in the production and sale of biopharmaceuticals. Along with subsidiaries, the Company operates its business through three segments. The Biopharmaceutical segment is involved in the manufacturing and sale of biopharmaceutical products such as... 
More about the company
Surperformance© ratings of Celltrion, Inc.
Trading Rating : Investor Rating :
More Ratings
Latest news on CELLTRION, INC.
2019CELLTRION : 3Q Net Profit Rose 13% on Year
DJ
2019CELLTRION : and Lonza Sign Contract to Manufacture Remsima Drug Substance
AQ
2019Novartis, Lonza deepen biosimilars push with MS, arthritis drug deals
RE
2019VEEVA : Celltrion Adopts Veeva Vault eTMF for Greater Visibility into Trial Acti..
AQ
2019CELLTRION : unveils P2 trial results for influenza antibody therapy
AQ
2019CELLTRION : Diverging from US, Canada Approves Biosimilar Rituximab in Both Onco..
AQ
2019CELLTRION : and iProgen Biotech announce partnership for development of novel AD..
AQ
2019CELLTRION : Partners with the Canadian Biotech Company, iProgen Biotech to Devel..
BU
2019CELLTRION : Completes Enrollment of Phase 3 Trial of CT-P17, Gives Update on Sub..
AQ
2019CELLTRION : licenses out hypertrophic cardiomyopathy treatment to Japan
AQ
2019CELLTRION : Healthcare wins biosimilar deals in Singapore and Thailand
AQ
2019Samsung Bioepis biosimilar to Roche's Herceptin wins FDA nod
RE
2019SOUTH KOREA'S CELLTRION AIMS TO SET : chairman
RE
2018FDA Approves Herceptin Biosimilar Herzuma
DJ
2018CELLTRION : European Medicines Agency Accepts Extension Marketing Authorisation ..
BU
More news
News in other languages on CELLTRION, INC.
2018SEVERIN SCHWAN : Roche cherche à se dégager de la menace des biosimilaires
2018USA : Teva espère lancer son traitement de la migraine dès septembre
More news
Analyst Recommendations on CELLTRION, INC.
More recommendations
Sector news : Biotechnology & Medical Research - NEC
02/20Anglo American Discloses All Mine Deaths in Industry Shift--Update
DJ
02/20Anglo American Discloses All Mine Deaths in Industry Shift -- Update
DJ
02/20Anglo American Discloses All Mine Deaths in Industry Shift
DJ
02/20GlaxoSmithKline Invests $50 Million in Biotech Startup's Cell-Therapy Program
DJ
02/19Five Prime Therapeutics In License Agreement with Seattle Genetics
DJ
More sector news : Biotechnology & Medical Research - NEC
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 18
Average target price 209 337,30  KRW
Last Close Price 177 000,00  KRW
Spread / Highest target 58,2%
Spread / Average Target 18,3%
Spread / Lowest Target -37,9%
EPS Revisions
Managers
NameTitle
Wu-Sung Ki Chief Executive Officer & Director
Jung-Jin Seo Chairman
Ho-Seop Lee Finance Director
Dong-Il Kim Independent Director
Joseph Lee Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
CELLTRION, INC.19 564
LONZA GROUP19.03%31 846
IQVIA HOLDINGS INC.5.77%31 512
SEATTLE GENETICS, INC.2.40%20 154
INCYTE CORPORATION-5.21%17 535
GALAPAGOS33.78%17 526